Universidad de Navarra

Running trials

• Recruiting

  Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.

  NCT07415720· Clinica Universidad de Navarra, Universidad de Navarra· Source

• Recruiting

  Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

  2022-502352-31-00· Phase 3· Amgen Inc.· Source

• Not yet recruiting

  SHARE Study: Social Chronic Heart Failure Person-centred cARE Intervention

  NCT06701916· Clinica Universidad de Navarra, Universidad de Navarra· Source

• Active, not recruiting

  Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

  NCT06149650· Cardiovascular and Interventional Radiological Society of Europe· Source

• Recruiting

  Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality

  NCT06338215· Clinica Universidad de Navarra, Universidad de Navarra· Source

• Recruiting

  Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  NCT04068597· Phase 1/2· CellCentric Ltd.· Source

• Active, not recruiting

  A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

  NCT03873402· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  Childhood Obesity Risk Assessment Longitudinal Study

  NCT06317883· Consorcio Centro de Investigación Biomédica en Red (CIBER)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes2 recruiting
• Acute myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Heart failure1 recruiting
• Liver cirrhosis1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Completed

  TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines in Adults With ER+ Advanced or Metastatic Breast Cancer, Sub-study C (ARV-471 and Samuraciclib)

  NCT06125522· Phase 1/2· Pfizer Inc.· Source

• Completed

  Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY)

  NCT06576232· Median Technologies· Source

• Completed

  Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

  NCT06751576· Median Technologies· Source

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Amgen Inc.· Source

• Terminated

  A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT04244656· Phase 1· CRISPR Therapeutics AG· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source